Want to see JP:7702 full AI Analyst Report?
7702 Stock Chart & Stats
¥442.00
-¥3.00(-0.69%)
At close: 4:00 PM EST
¥442.00
-¥3.00(-0.69%)
Day’s Range― - ―
52-Week Range¥418.00 - ¥464.00
Previous CloseN/A
Volume24.60K
Average Volume (3M)25.96K
Market Cap
¥10.87B
Enterprise Value¥31.13B
Total Cash (Recent Filing)¥6.20B
Total Debt (Recent Filing)¥23.36B
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.85%
Share Statistics
EPS (TTM)-11.35
Shares Outstanding24,733,465
10 Day Avg. Volume29,090
30 Day Avg. Volume25,963
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.25
Price to Sales (P/S)0.16
P/FCF Ratio-11.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Consumables Revenue ModelJMS's core business sells single-use consumables tied to clinical procedures (dialysis, infusion, transfusion), creating predictable repeat demand. This attachment to procedure volume yields durable, recurring revenue streams and steady replenishment orders that support mid-term cash generation and customer stickiness.
Reasonable Gross MarginSustaining a gross margin near 23% provides built-in buffer to cover fixed costs and absorb moderate input cost increases. For a disposables-focused medical supplier, this margin level supports reinvestment in product quality and distribution while preserving long-term profitability potential if revenue stabilizes.
Positive Operating Cash Flow TrendConsistent positive operating cash flow, despite volatile free cash flow, indicates the core business converts sales into cash. That operating cash generation underpins working capital needs, funds routine capex, and reduces reliance on external financing over the medium term if management keeps margins and volumes stable.
Bears Say
Deteriorating ProfitabilityA recent net loss and consecutive revenue declines signal weakening operating leverage and demand pressure. Persistent earnings volatility undermines retained earnings and limits capacity to invest in product development or commercial expansion, challenging sustainable margin recovery over the medium term.
Rising LeverageLeverage increasing materially over several years reduces financial flexibility should earnings remain muted. Higher debt loads tighten interest and principal obligations, constrain strategic choices, and raise refinancing risk in adverse conditions, weakening the firm's ability to fund growth or weather shocks.
Volatile And Negative Free Cash FlowFrequent negative free cash flow episodes limit capacity to delever, pay steady dividends, or invest in new products. Negative FCF in recent years increases reliance on balance sheet reserves or external financing, which is riskier with rising leverage and weak profitability, constraining medium-term strategic flexibility.
JMS Co., Ltd. News
7702 FAQ
What was JMS Co., Ltd.’s price range in the past 12 months?
JMS Co., Ltd. lowest stock price was ¥418.00 and its highest was ¥464.00 in the past 12 months.
What is JMS Co., Ltd.’s market cap?
JMS Co., Ltd.’s market cap is ¥10.87B.
When is JMS Co., Ltd.’s upcoming earnings report date?
JMS Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 39 days.
How were JMS Co., Ltd.’s earnings last quarter?
JMS Co., Ltd. released its earnings results on May 12, 2026. The company reported -¥27.71 earnings per share for the quarter, missing the consensus estimate of N/A by -¥27.71.
Is JMS Co., Ltd. overvalued?
According to Wall Street analysts JMS Co., Ltd.’s price is currently Overvalued.
Does JMS Co., Ltd. pay dividends?
JMS Co., Ltd. pays a Semiannually dividend of ¥8.433 which represents an annual dividend yield of 3.85%. See more information on JMS Co., Ltd. dividends here
What is JMS Co., Ltd.’s EPS estimate?
JMS Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JMS Co., Ltd. have?
JMS Co., Ltd. has 24,733,465 shares outstanding.
What happened to JMS Co., Ltd.’s price movement after its last earnings report?
JMS Co., Ltd. reported an EPS of -¥27.71 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.179%.
Which hedge fund is a major shareholder of JMS Co., Ltd.?
Currently, no hedge funds are holding shares in JP:7702
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
JMS Co., Ltd.
JMS Co., Ltd., established in 1947 and headquartered in Hiroshima, Japan, specializes in the development, manufacture, distribution, and global trade of a wide array of medical devices and pharmaceuticals. Its extensive product catalog serves both Japanese and international markets, addressing diverse medical needs. The company provides a comprehensive range of items for infusion and transfusion therapy, including infusion/transfusion sets (some featuring needle-free access ports), single-use needles and syringes, secure scalp vein sets, safe intravenous catheters, extension tubing, oral and enteral feeding systems, infusion and syringe delivery pumps, devices for administering semi-solid nutritional supplements, as well as blood bags, blood collection scales and mixers, high-frequency tube sealing equipment, and serum collection apparatus. For general medical use, JMS offers essential consumables for healthcare institutions such as surgical and examination gloves (both latex and plastic), treatment drapes, surgical gowns, protective masks and caps, drainage receptacles, and surgical adhesive tapes. Furthermore, JMS is a key supplier for hemodialysis and peritoneal dialysis, providing centralized dialysate delivery systems, hemodialysis units, AV fistula needles, systems designed to prevent accidental needlestick injuries, blood tubing sets for hemodialysis, dialyzers, pre-filled syringes, complete hemodialysis kits, single-patient dialysis devices, dialysis solutions for Continuous Ambulatory Peritoneal Dialysis (CAPD), and automated peritoneal dialysis equipment. The company also offers specialized products for cardiovascular therapy, which encompass cardiopulmonary support systems, membrane oxygenators, heat exchange units, pacemakers, microcatheters, and blood tubing sets for cardiopulmonary bypass.
Technical Analysis
Options Prices
Currently, No data available
---



